This drug could treat heart attack-induced cardiac arrest

Researchers from King’s College London have developed a groundbreaking drug, OCT2013, that could potentially transform the way sudden cardiac deaths from heart attacks are prevented.

Published in the British Journal of Pharmacology by Dr. Mike Curtis and his team, this study offers hope for a solution to a critical health issue affecting thousands annually in the UK alone.

Heart attacks often lead to a dangerous condition called ventricular fibrillation (VF), where irregular heart rhythms prevent the heart from pumping blood effectively, swiftly leading to death.

Traditionally, drugs like lidocaine have been used to manage VF due to their ability to stabilize the heart’s electrical activity. However, lidocaine’s severe side effects on other parts of the heart and nervous system have restricted its use to controlled hospital settings, administered via IV.

The breakthrough with OCT2013 lies in its innovative mechanism. The drug, structurally similar to lidocaine, remains inactive until it encounters the low-oxygen environment of ischemic heart tissue—the exact location where heart attacks compromise blood flow.

Once there, OCT2013 converts into active lidocaine, targeting the affected area without impacting other regions of the body, thereby avoiding the typical side effects associated with lidocaine.

In experiments using a heart attack model in rats, OCT2013 successfully prevented sudden cardiac death by mimicking the beneficial effects of lidocaine on the ischemic parts of the heart, without the unwanted broader impacts. Chemical analyses confirmed that OCT2013 converted into lidocaine specifically in the ischemic heart regions.

This discovery not only opens the door to potentially life-saving treatment options for patients experiencing heart attacks outside of hospital settings but also represents the creation of a new class of drugs focused on condition-specific activation.

The targeted nature of OCT2013 means it could one day be administered immediately following heart attack symptoms, drastically reducing the risk of death from VF before emergency medical services arrive.

The implications of this study are profound, highlighting a significant advancement in cardiac care and emergency treatment of heart attacks.

The researchers are optimistic that OCT2013 could soon lead to the development of a drug that can be prescribed in non-hospital settings, significantly reducing the number of preventable deaths associated with heart attacks each year.

Source